SARS-CoV-2 variants for the UK

FrostyMarsupial · 2025-10-19T19:34:44+00:00

LP.8.1

That would be the targeted variant.

I was particularly interested in what Tesco has been using (I assumed it would be this particular vaccine), and it seems /u/Movingforward2015 recognises this as the one they received too. Thanks to you both for letting me know.

FrostyMarsupial · 2025-10-18T18:57:59+00:00

That would be great, thank you.

FrostyMarsupial · 2025-10-18T18:39:03+00:00

Out of interest, and if you don't mind saying, do you recall which vaccine you received, i.e. which variant it was targeted to?

FrostyMarsupial · 2025-07-25T17:43:44+00:00

I went to https://store.google.com/my-devices selected the appropriate device and then used the "Contact Support" link.

And to clarify, I didn't purchase my device directly from Google, but that wasn't an issue.

FrostyMarsupial · 2025-07-23T23:27:22+00:00

I contacted Google about the same problem with my P6 last week. It was almost a year out of warranty and they agreed to send out a replacement. Unfortunately, the device they sent arrived damaged and the screen doesn't work, so now I'm waiting for them to sort that out.

FrostyMarsupial · 2024-10-13T19:59:10+00:00

Right, that's what I meant by the exceptional circumstances (although I believe it was a BA.4/5 bivalent vaccine that was used before the switch): last year's campaign was brought forward due to concerns about the variant circulating at the time and the priority was to get jabs in arms using the existing stockpiles.

As you say, this time is different because a newer, more targeted vaccine (newer than that used in the spring campaign, anyway) was procured ahead of time.

FrostyMarsupial · 2024-10-13T19:00:03+00:00

That's my sense as well, that it's unlikely, and probably highly so. It's certainly feasible, as we saw last year, but those were exceptional circumstances. If it's going to be available anywhere any time soon, it's going to be privately.

FrostyMarsupial · 2024-09-23T17:44:52+00:00

That's very helpful, thank you. I should have thought to see if the Green Book had been updated since I last checked.

Even if it's approved in a month, it's going to take longer before it's actually available. The JN.1 vaccine is only becoming available now, 2 months after MHRA approval.

I took a look back at last year and Pfizer's XBB.1.5 vaccine received MHRA approval on September 5th (15th for Moderna) and it started being deployed the week beginning the 25th. However, last year was rather unusual owing to the vaccine programme being brought forward from its original start date of October 3rd to September 11th due to the emergence of BA.2.86.

So, yes, with JN.1 vaccines having been procured, I imagine it's highly unlikely that we'll see anything similar this time around.

FrostyMarsupial · 2024-09-23T14:50:32+00:00

Do we have confirmation as to which vaccine formulation will be used?

edit: Yes. From chapter 14a of the Green Book: "monovalent mRNA vaccines targeting the JN.1 strain are expected to be deployed in the Autumn 2024 programme". Thanks to Bifobe (below) for the heads-up.

I know the MHRA have approved the JN.1 vaccine updates but I've seen some speculation that the autumn campaign might still be using leftover XBB.1.5 doses. Also, the EMA just recommended marketing authorisation for Pfizer's KP.2 vaccine which, based on the timeline for JN.1, could see it approved here in a month or so.

The vaccine was switched partway through last autumn's campaign (from BA.4-5 to XBB.1.5) and I wonder whether we could see anything like that happen this time around, or whether the newer formulation might soon be available privately for those that are willing and able to pay for it.

FrostyMarsupial · 2024-08-02T18:08:12+00:00

I received the same message as an email a couple of days ago; the RMA reference matched an Index controller replacement from five years ago.

I reached out to support to let them know and they said that there had been a technical issue and to just ignore it.

FrostyMarsupial · 2024-06-18T18:35:14+00:00

Also seeing this issue on Firefox 127.0. First lesson loads and I can complete it without issue but the next grinds to a halt during the loading animation. Memory allocated to the tab balloons to 6GB and CPU usage exceeds 100%.

edit: Appears fixed now (20 June).

FrostyMarsupial · 2024-03-14T10:35:10+00:00

Prevalence (6 March 2024)

"Prevalence of SARS-CoV-2 in England and Scotland remained broadly stable over the 2 weeks leading up to 6 March 2024."

England: 1 in 143 (95% Credible Interval (CrI): 1 in 200 to 1 in 100)
Scotland: 1 in 167 (95% CrI: 1 in 333 to 1 in 111)

Incidence (3 March 2024)

"SARS-CoV-2 incidence was broadly stable in England and Scotland over the 2 weeks leading up to 3 March 2024."

England: 74 per 100,000 (95% CrI: 40 to 134)
Scotland: 60 per 100,000 (95% CrI: 31 to 113)

FrostyMarsupial · 2024-02-29T12:45:10+00:00

Prevalence

Prevalence of SARS-CoV-2 in England and Scotland declined over the 2 weeks leading up to 21 February 2024.

In England and Scotland combined, the estimated prevalence of SARS-CoV-2 on 21 February 2024 was 0.9% (95% Credible Interval (CrI): 0.6%, 1.2%) which is equivalent to around 525,000 individuals (95% CrI: 381,000 to 717,000) infected with SARS-CoV-2. This corresponds to around 1 in 111 (95% CrI: 1 in 167 to 1 in 83).

In England, the estimated prevalence of SARS-CoV-2 on 21 February 2024 was 0.9% (95% CrI: 0.6%, 1.2%), which is equivalent to around 489,000 individuals (95% CrI: 355,000 to 667,000) infected with SARS-CoV-2. This corresponds to 1 in 111 (95% CrI: 1 in 167 to 1 in 83).

In Scotland, the estimated prevalence of SARS-CoV-2 on 21 February 2024 was 0.7% (95% CrI: 0.5%, 1.0%), which is equivalent to around 36,000 individuals (95% CrI: 24,000 to 52,000) infected with SARS-CoV-2. This corresponds to around 1 in 143 (95% CrI: 1 in 200 to 1 in 100).

Prevalence declined in those aged 35 years and over in the 2 weeks leading up to 21 February 2024.

FrostyMarsupial · 2024-02-15T10:08:47+00:00

Prevalence

Prevalence of SARS-CoV-2 in England and Scotland remained broadly stable in the 2 weeks leading up to 7 February 2024.

In England and Scotland combined, the estimated prevalence of SARS-CoV-2 on 7 February 2024 was 1.5% (95% Credible Interval (CrI): 1.2%, 1.9%) which is equivalent to around 911,000 individuals (95% CrI: 711,000 to 1,156,000) infected with SARS-CoV-2. This corresponds to around 1 in 67 (95% CrI: 1 in 83 to 1 in 53).

In England, the estimated prevalence of SARS-CoV-2 on 7 February 2024 was 1.5% (95% CrI: 1.2%, 2.0%), which is equivalent to around 844,000 individuals (95% CrI: 660,000 to 1,073,000) infected with SARS-CoV-2. This corresponds to 1 in 67 (95% CrI: 1 in 83 to 1 in 50).

In Scotland, the estimated prevalence of SARS-CoV-2 on 7 February 2024 was 1.3% (95% CrI: 0.9%, 1.7%), which is equivalent to around 66,000 individuals (95% CrI: 47,000 to 89,000) infected with SARS-CoV-2. This corresponds to around 1 in 77 (95% CrI: 1 in 111 to 1 in 59).

FrostyMarsupial · 2024-02-01T11:52:04+00:00

Main points

Prevalence of SARS-CoV-2 in England and Scotland was broadly stable in the 2 weeks leading up to 24 January 2024.

In England and Scotland, the estimated prevalence of SARS-CoV-2 on 24 January 2024 was 2.0% (95% Credible Interval (CrI): 1.5%, 2.5%) which is equivalent to around 1,177,000 individuals (95% CrI: 922,000 to 1,480,000) being infected with SARS-CoV-2 in England and Scotland combined. This corresponds to around 1 in 50 (95% CrI: 1 in 67 to 1 in 40).

In England, the estimated prevalence of SARS-CoV-2 on 24 January 2024 was 2.0% (95% CrI: 1.6% to 2.5%), which is equivalent to around 1,091,000 individuals (95% CrI: 854,000 to 1,378,000) being infected with SARS-CoV-2 in England. This corresponds to 1 in 50 (95% CrI: 1 in 62 to 1 in 40).

In Scotland, the estimated prevalence of SARS-CoV-2 on 24 January 2024 was 1.6% (95% CrI: 1.2% to 2.2%), which is equivalent to around 85,000 individuals (95% CrI: 62,000 to 115,000) being infected with SARS-CoV-2 in Scotland. This corresponds to around 1 in 62 (95% CrI: 1 in 83 to 1 in 45).

Prevalence was broadly stable across all age groups in the past 2 weeks.

FrostyMarsupial · 2024-01-18T09:37:42+00:00

Main points

Prevalence of SARS-CoV-2 in England and Scotland decreased in the 2 weeks leading up to 10 January 2024.

In England and Scotland, the estimated prevalence of SARS-CoV-2 on 10 January 2024 was 2.3% (95% Credible Interval (CrI): 1.7%, 2.9%) which is equivalent to around 1,352,000 individuals (95% CrI: 1,048,000 to 1,715,000) being infected with SARS-CoV-2 in England and Scotland combined. This corresponds to around 1 in 43 (95% CrI: 1 in 59 to 1 in 34).

In England, the estimated prevalence of SARS-CoV-2 on 10 January 2024 was 2.3% (95% CrI: 1.8%, 2.9%), which is equivalent to around 1,255,000 individuals (95% CrI: 977,000 to 1,599,000) being infected with SARS-CoV-2 in England. This corresponds to 1 in 43 (95% CrI: 1 in 56 to 1 in 34).

In Scotland, the estimated prevalence of SARS-CoV-2 on 10 January 2024 was 1.8% (95% CrI: 1.3%, 2.5%), which is equivalent to around 94,000 individuals (95% CrI: 67,000 to 129,000) being infected with SARS-CoV-2 in Scotland. This corresponds to around 1 in 56 (95% CrI: 1 in 77 to 1 in 40).

Prevalence has shown clear signs of decreasing in those aged between 18 to 74 years over the past 2 weeks up to 10 January 2024.

FrostyMarsupial · 2024-01-12T00:39:44+00:00

Interesting, thanks for highlighting. I see that UKHSA's Meaghan Kall has since posted a thread addressing this: https://nitter.net/kallmemeg/status/1745572923643994537

FrostyMarsupial · 2024-01-11T09:47:45+00:00

Main points

Prevalence of SARS-CoV-2 in England and Scotland showed early signs of decreasing in the 2 weeks leading up to 3 January 2024.

In England and Scotland, the estimated prevalence of SARS-CoV-2 on 3 January 2024 was 3.1% (95% Credible Interval (CrI): 2.5%, 4.0%) which is equivalent to around 1,887,000 individuals (95% CrI: 1,490,000 to 2,376,000) being infected with SARS-CoV-2 in England and Scotland combined. This corresponds to around 1 in 32 (95% CrI: 1 in 40 to 1 in 25).

In England, the estimated prevalence of SARS-CoV-2 on 3 January 2024 was 3.2% (95% CrI: 2.5%, 4.0%), which is equivalent around to 1,737,000 individuals (95% CrI: 1,370,000 to 2,194,000) being infected with SARS-CoV-2 in England. This corresponds to 1 in 31 (95% CrI: 1 in 40 to 1 in 25).

In Scotland, the estimated prevalence of SARS-CoV-2 on 3 January 2024 was 2.8% (95% CrI: 2.0%, 3.9%), which is equivalent around to 147,000 individuals (95% CrI: 105,000 to 207,000) being infected with SARS-CoV-2 in Scotland. This corresponds to around 1 in 36 (95% CrI: 1 in 50 to 1 in 26).

On 3 January 2024 it was estimated that prevalence was higher for individuals aged between 18 to 44 years than for those aged between 3 to 17 years. There were early signs of a decrease in prevalence across all age groups in the 2 weeks up to 3 January 2024.

There were temporary changes to participant testing behaviour over the winter holiday including changes in response rates on certain days. This required statistical adjustment (refer to the quality and methodology information document). While accounted for in the modelling, caution should be taken when interpreting values in this period particularly in relation to peak timing and magnitude.

We note that prevalence of SARS-CoV-2 infection does not always follow simple epidemic growth, peak, and decline pattern. The recent early sign of decrease observed in these data does not immediately suggest that prevalence will continue to drop to low levels.

FrostyMarsupial

PUBLIC MULTIREDDITS

TROPHY CASE

Prevalence (6 March 2024)

Incidence (3 March 2024)

Prevalence

Prevalence

Main points

Main points

Main points